Background {#Sec1}
==========

The risk of an unexpected ovarian malignancy is estimated to be 1% or less in premenopausal women and 3.0% in postmenopausal women \[[@CR1]\]. The majority of these adnexal cysts and masses are managed by general gynaecologists, which may lead to inadequate staging of ovarian cancer during the primary operation \[[@CR2], [@CR3]\]. As a consequence these patients have two options: (1) second surgery to be optimally staged since optimal staging is an independent prognostic parameter for survival or (2) chemotherapy, since non-optimal staged patients benefit from adjuvant chemotherapy \[[@CR4]\]. In patients there are subgroups who have little or nothing to gain from adjuvant chemotherapy and it appears to be safe to withhold adjuvant chemotherapy from patients with early-stage disease who are optimally staged \[[@CR5]\].

The traditional procedure for staging ovarian cancer is through laparotomy with a midline incision, exposing the whole peritoneal cavity \[[@CR6]\]. Since 1994 several mainly small studies have been published by a limited group of centres on the results of a laparoscopic approach to the staging of early ovarian cancer \[[@CR7]--[@CR22]\]. Laparoscopic staging proves to be accurate and feasible in ovarian cancer patients and has the advantages of minimal invasive surgery. These advantages include less blood loss \[[@CR8], [@CR17], [@CR18], [@CR21]\], optical magnification of laparoscopic inspection \[[@CR12], [@CR14], [@CR17]\], shorter hospital stay \[[@CR8], [@CR10]--[@CR12], [@CR16]--[@CR18], [@CR21]\], shorter time interval to adjuvant chemotherapy \[[@CR10], [@CR17]\] and faster return of bowel movements \[[@CR17], [@CR18]\]. Laparoscopic staging provides similar complication rates as open surgery \[[@CR8], [@CR16]\]. Despite studies proving the feasibility, accuracy and safety of laparoscopic staging in early ovarian cancer, laparotomy is still advocated by the majority of centres. One of the reasons for a slow implementation of minimal invasive techniques in complex oncological surgery may be a long learning curve. The learning curve of the laparoscopic staging procedure in ovarian cancer has never been addressed. However Eltabbakh et al. demonstrated clearly a learning curve in the laparoscopic staging procedure for endometrial cancer \[[@CR23]\]. Our study primarily focuses on the learning curve of a single surgeon in the laparoscopic staging procedure in women with early ovarian cancer and the surgical outcome of these patients.

Patients and methods {#Sec2}
====================

A retrospective chart review was undertaken and identified 25 cases of laparoscopic staging of apparent early-stage ovarian cancer, all operated by the same surgeon (RV) in the period from June 2001 to October 2009. To obtain clinical and pathologic information, we reviewed the patient\'s medical records. The following information was obtained: age, BMI, surgical procedure, pre- and postoperative FIGO stage, histopathology, days between first operation and staging laparoscopy, operation time, estimated blood loss, number of pelvic and para-aortic nodes, complications, hospital stay, nature of subsequent treatment, delay in chemotherapy, length of follow-up, recurrence and mortality. Postoperative complications were defined as occurring within 30 days after the procedure. Most ovarian carcinomas were diagnosed at final histopathology, after a first operation where a malignancy was not anticipated. After the final pathologic diagnosis, patients were scheduled for a laparoscopic staging procedure. Preoperative investigations after the diagnosis of malignancies included: CA 125 measurement, ultrasound and CT scan. All but two patients were clinically expected to have stage I disease, the other two patients were expected to have stage II disease. All histological types of ovarian cancers were included. Patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. Table 1Patient characteristicsCharacteristicsNumberPatients25Mean age in years (range)49.7 (18--79)BMI in kg/m^2^ (range)24.6 (17.4--36.5)Histological types Adenocarcinoma16 Clear cell4 Borderline4 Other1FIGO stage (before staging) IA12 IB1 IC9 IIC2 Unknown1Tumour grade Grade 110 Grade 27 Grade 35 Unknown3Procedures at initial surgery Cystectomy3 Adnectomy11 Bilateral adnectomy5 Hysterectomy + adnectomy1 Hysterectomy + bilateral adnectomy4 No initial surgery1Ovarian preservation procedure at secondary surgery4 Mean age in years (range)32.3 (18--41) Histologic type  Borderline2  Adenocarcinoma2

Laparoscopic staging procedure {#Sec3}
------------------------------

All patients were operated by the same surgeon, using the same technique. Four trocar ports were used. The first 11-mm trocar was inserted into the umbilical area, one 10-mm trocar above the symphysis, one 10-mm at the left upper quadrant and a 5-mm trocar at the right upper quadrant of the lower abdomen. A thorough exploration of all pelvic and abdominal organs and peritoneal surface was conducted. Cytological washings of the peritoneal cavity were taken, and any suspicious lesion was biopsied next to random biopsies from the diaphragm, left and right paracolic gutter, peritoneal reflection of the bladder and pouch of Douglas. Residual adnexal tissue and/or the residual infundibulo-pelvic ligament on the side of the originally involved ovary was removed. Comprehensive surgical staging further involved transperitoneal lymph node sampling from the pelvic and para-aortic regions up to the left renal vein, followed by an infra- or supracolic omentectomy (using a vessel-sealing technique). A hysterectomy was not routinely performed. The uninvolved ovary, when unsuspicious on visual inspection, was left in situ in fertility-sparing procedures, in which case a wedge biopsy was taken.

Learning curve {#Sec4}
--------------

To assess the effect of increasing experience, of the surgeon in the laparoscopic staging procedure, the patients were arranged in chronological order based on the date of their staging surgery. The patients were divided in equal groups according to three periods. Group I (*n* = 9) had surgery in 2001--2003, group II (*n* = 8) had surgery in 2004--2006 and group III (*n* = 8) had surgery in 2007--2009. The groups were compared for surgical outcomes: operating time, estimated blood loss, number of lymph nodes harvested, complications and hospital stay.

Literature search {#Sec5}
-----------------

A PubMed search was performed to retrieve all articles concerning laparoscopic staging procedures in women with ovarian cancer between 1980 and January 2010. Search terms used included: 'ovarian cancer', 'early ovarian cancer', 'early-stage ovarian cancer', 'ovarian carcinoma', 'ovarian neoplasm\'s', 'adnexal tumor', 'fallopian tube neoplasm's', 'fallopian tube cancer', 'laparoscopy', 'laparoscopic surgery', 'staging', 'staging surgery' and 'laparoscopic staging'. The relevant studies we found were compared to our series on the basis of above parameters.

Statistical analysis {#Sec6}
--------------------

To analyse non-continuous variables we used the Kruskal--Wallis test. *P* values \<0.05 were considered significant. Statistic analysis was performed using the statistical software package SPSS 15.0 (SPSS Inc, Chicago, IL).

Findings {#Sec7}
========

A total of 25 patients underwent laparoscopic staging for presumed early-stage ovarian cancer. Most patients (*n* = 24) had a secondary staging (restaging) procedure after referral, one patient was primarily staged. Patient\'s characteristics are outlined in Table [1](#Tab1){ref-type="table"}. The surgical outcome is outlined in Table [2](#Tab2){ref-type="table"}. The median operation time was 235 min (range 100--285, mean 224). Intraoperative complications were two arterial bleedings. One patient lost 1,000 ml of blood, the other patient 1,500 ml and required a blood transfusion during surgery. No conversion to laparotomy was needed. Postoperative complications were two port site haematomas in different patients, which resolved spontaneously. In 19 patients pelvic lymph nodes were collected (median 8.0, mean 12.2) and in 24 patients\' para-aortic lymph nodes were collected (median 6.0, mean 5.8). The median number of total lymph nodes harvested was 8.0 (range 3--31, mean 12.2). Table 2Surgical outcomeVariableOperation time (min)235 (100--285)Estimated blood loss (ml)100 (10--1,500)Total LNN^a^ Pelvic lymph nodes (*n* = 19)8.0 (3--31) Para-aortic lymph nodes (*n* = 24)6.0 (2--12) Overall (*n* = 24)8.0 (3--31)Time between operations (days)54 ± 21Upstaging (*n*)8 (32%)Intraoperative complications (*n*)2 (8%)Postoperative complications (*n*)2 (8%)Postoperative hospital stay (days)4.0 (2--6)Time to adjuvant chemotherapy (days)21 (±10.3)Follow-up (months)43 (±31.5)Data are expressed as median (range), mean±standard deviation or number (in percentage)^a^In those patients where a pelvic and/or para-aortic lymphadenectomy was performed

The operating time and total number of lymph nodes collected are shown in a scatter plot chronologically arranged by date of surgery (Fig. [1](#Fig1){ref-type="fig"}). The operating times are widely spread, but the total number of lymph nodes harvested show an increase during time. Based on final pathological assessment, eight patients were upstaged. From presumed stage IA, two patients were upstaged to stage IC, one to stage IIB, one to stage IIC, one to stage IIIA, two patients were upstaged from presumed stage IC to stage IIIC and one patient was upstaged from IIC to stage IIIC. Eleven patients did not need adjuvant chemotherapy; all other patients received adjuvant chemotherapy. These patients all had stage IC or higher or a grade 3 tumour. Mean duration of follow-up was 43 months. Five patients had a recurrence. One mucinous borderline tumour (2001 FIGO stage IC, no lymph node dissection) and four carcinomas recurred. In two patients recurrence appeared as carcinomatous pleuritis or peritonitis. Both these patients were completely staged and had a clear cell carcinoma (2003 FIGO IIC and 2006 FIGO stage IC); they died from the disease. The other patients are all alive without disease. Fig. 1Operating time and number of lymph nodes. Surgical procedures in chronological order: operating time (*n* = 25) and total number of lymph nodes \[pelvic + para-aortal (*n* = 24) (scatter plot)\]

To demonstrate a possible learning curve over time, the patients were divided into three groups and compared with respect to operating time, estimated blood loss, hospital stay and number of pelvic and para-aortic lymph nodes. Median operating time, estimated blood loss and hospital stay did not show a significant difference between the three groups. But there was a significant increase in the total number of lymph nodes collected (*P* = 0.003, Table [3](#Tab3){ref-type="table"}). Table [4](#Tab4){ref-type="table"} shows an overview of the original literature regarding the laparoscopic staging procedure in early ovarian cancer. We added the present study in this table. Table 3Surgical outcome in time periodsGroup I (first period), *n* = 9Group II (second period), *n* = 8Group III (third period), *n* = 8*P* valueOperative time (min)225.0 (100--260)245.0 (145--285)207.5 (181--270)0.095EBL (ml)50.0 (10--1,000)50.0 (20--200)100.0 (20--1,500)0.682Total number lymph nodes^a^6.5 (3--17)8.0 (3--21)21.0 (7--31)0.003 Pelvic^a^7.5 (1--12)3.0 (1--13)13.0 (4--19)0.023 Para-aortic^a^5.5 (2--7)4.0 (2--8)9.0 (3--12)0.017Hospital stay (days)3.0 (2--5)4.0 (3--6)3.5 (3--6)0.069Data expressed as medians with range^a^In those patients where a pelvic and/or para-aortic lymphadenectomy was performedTable 4Overview of literature for the laparoscopic staging procedure in early-stage ovarian cancerLaparoscopyNumberRestaging/primary stagingOR time (min)Delay (weeks)Hospital stay (days)PLN (*n*)PALN (*n*)EBL (ml)Upstaging (*n*, %)Compl (*n*, %)Follow-up (months)R (*n*)M (*n*)Present series2524/1224 (100--285)7.3 (3.1--13.3)4.0 (2--6)13.8 (3--31)5.8 (2--12)193 (10--1,500)8 (32%)4 (16%)43 (1--116)52Nezhat et al. \[[@CR16]\]369/25229 (59--386)NA2.37 (1--5)14.84 (0--45)12.23 (0--53)195 (25--500)7 (19.4%)4 (11.1%)5630Muzii et al. \[[@CR15]\]2727/0180 (130--300)6.8 (2--9)3 (2--7)NANA200 (100--700)7 (26%)1 (3.7%)20 (7--38)10Jung et al. \[[@CR12]\]245/19253.7 ± 65.7NA10.6 ± 4.022.5 ± 8.911.0 ± 5.8567.0 ± 170.910 (41.7%)1 (4.2%)10 (2--39)11Park et al. \[[@CR17]\]197/12221 ± 8319 (7--34)8.9 ± 6.127.2 ± 9.76.6 ± 6.2240 ± 2284 (21.1%)2 (10.5%)17 (2--40)00Park et al. \[[@CR18]\]176 / 11303.8 ± 84.935.89.4 ± 4.113.7 ± 5.68.9 ± 7.1231.2 ± 117.91 (5.9%)2 (11.8%)19 (5--56)21Colomer et al. \[[@CR10]\]207/13223 (180--320)4.7 (2--11.4)3.2 (1--7)18 (14--21)11.3 (7--23)NA4 (20%)2 (10%)24.7 (1--61)10Ghezzi et al. \[[@CR11]\]155/10377 ± 478 (5--14)3 (2--12)25.2 ± 9.36.5 ± 3.9250 (50--1,000)4 (26.7%)2 (6.7%)16 (4--33)00Chi et al. \[[@CR8]\]2013/7321 ± 64NA3.1 ± 0.7L, 5.8 ± 2.9L, 2.9 ± 1.7235 ± 138NA0NANANAR, 6.5 ± 3.9R, 3.8 ± 1.8Spirtos et al. \[[@CR21]\]5858/0187.9 ± 59.8NA3.35 ± 5.10L, 9.0 ± 6.0L, 5.3 ± 3.3171.9 ± 1288 (13.8%)11 (19%)NANA0R, 9.6 ± 5.2R, 5.0 ± 3.4Leblanc et al. \[[@CR14]\]5342/11238 (120--370)8.3 ± 4.83.1 (1--5)14 (4--27)20 (7--40)NA8 (19%)4 (7.5%)54 (8--116)52Krivak et al. \[[@CR30]\]190/19201 (90--350)NA2 (1--8)NANA271 (50--1,500)7 (36%)4 (16%)32NANATozzi et al. \[[@CR22]\]2411/13176 (102--306)12 (4--21)7 (5--12)19.8 (14--29)19.6 (5--35)NANA1 (4.1%)46 (2--72)20Leblanc et al. \[[@CR13]\]2825/3230 ± 67.58.3 (2--26)3.3 (1--6)13.7 (4--27)19.7 (5--40)NA6 (21%)1 (3.7%)38 (2--89)11Amara et al. \[[@CR7]\]43/1290 (190--335)NA1.75 (1--2)NANANANA0NANANAPomel et al. \[[@CR19]\]1010/0313NA4.75 (2--8)7.1 (3--13)8.8 (6--12)NANA2 (20%)NANANAChilders et al. \[[@CR9]\]145/9149 (120--240)NA1.6 (0--3)NANANA8 (57%)2 (14.3%)NANANAQuerleu and Leblanc \[[@CR20]\]99/0227 (130--360)NA2.8 (1--5)NA8.6 (5--17)\<3000%0NANANALaparotomyPark et al. \[[@CR17]\]33NA275 ± 6313 (9--16)14.5 ± 5.633.9 ±14.58.8 ± 8.1568 ± 4517 (21.2%)9 (27.3%)23 (1--44)00Park et al. \[[@CR18]\]19NA290 ± 1213214.1 ± 4.219.3 ± 10.16.4 ± 3.9505.3 ± 279.86 (31.6%)7 (36.8%)14 ( 5--61)00Ghezzi et al. \[[@CR11]\]19NA272 ± 81NA7 (4--14)25.1 ± 5.87 ± 4.5400 (150--1,000)6 (31.6%)8 (42.1%)60 (32--108)40Chi et al. \[[@CR8]\]30NA276 ± 68NA5.8 ± 2.6L, 7.1 ± 4.3L, 4.8 ± 4.2367 ± 208NA2 (7%)NANANAR, 7.6 ± 3.8R, 4.4 ± 2.8Spirtos et al. \[[@CR21]\]17NA218 ± 73NA7.31 ± 9.3L, 8.2 ± 5.0L, 4.6 ± 2.6352.8 ± 415.08 (47%)NANANA0R, 9.14 ± 9.9R, 4.4 ± 2.7*Delay* between initial OR and staging, *PLN* pelvic lymph nodes, *PALN* para-aortic lymph nodes, *EBL* estimated blood loss, *Compl* complications, *R* Recurrence, *M* Mortality (depending on what authors describe *NA* not available, *−* range, *±* standard deviation)

Discussion {#Sec8}
==========

We expected that with increase of the surgeon\'s experience in performing laparoscopic staging procedures, the effect would be a shorter operating time and a higher number of pelvic and para-aortal lymph nodes harvested. However we did not find a decrease in operating time as a function of the surgeon\'s experience in laparoscopic staging. This might be due to the relatively limited number of cases. We did find a significant increase in the amount of lymph nodes harvested. The variation in operating time may be due to differences in the extent of surgery performed during laparoscopic staging. In the relatively small group we were unable to correct for these differences. Depending on what is done at initial surgery, the staging procedure for early ovarian cancer should be completed at the second operation (restaging). In our series all patients had an omentectomy, which was usually performed infracolicly. In nine patients a unilateral and in three patients, a bilateral salpingo-oophorectomy was performed, four patients had an ovarian excision (to preserve fertility) and in nine patients, a bilateral salpingo-oophorectomy had already been performed during the initial surgery. In six patients (four carcinomas and two borderline tumours, all before 2004), there was no pelvic lymphadenectomy performed. In the earlier years, less emphasis was laid on the role of pelvic lymphadenectomy and during the years, the guidelines changed. In one patient, with a borderline tumour, a para-aortic lymphadenectomy was not performed. In one patient a hysterectomy was performed, and two patients had an appendectomy because of a mucinous tumour. A laparoscopic procedure including a hysterectomy takes longer. Childers et al. found a mean operating time of 149 min in patients who did not undergo a hysterectomy during their laparoscopic staging, and a mean operating time of 196 min in patients who did undergo a hysterectomy \[[@CR9]\]. We do not routinely perform a full hysterectomy in a laparoscopic staging procedure. In view of the lack of evidence that the uterus may be involved when the tumour (seemingly) does not extend beyond the ovaries, it is not justifiable to routinely include such, potentially harmful, operation \[[@CR24], [@CR25]\]. However in a case of endometroid ovarian carcinoma, we perform an endometrial curettage. We did not find recurrences in a retained uterus, confirming that it is safe to leave the hysterectomy. Regarding fertility-sparing surgery in early ovarian cancer, several authors reported that it seems to be safe to leave the uterus and the remaining ovary \[[@CR15]\]. Despite the fact that we couldn\'t find a decrease in operating time, it is likely that the increase of lymph nodes harvested demonstrates a learning curve in the laparoscopic management of women with early-stage ovarian carcinoma. This aspect of the learning curve was also found by Eltabbakh et al. In this study, a laparoscopic assisted vaginal hysterectomy with bilateral salpingo-oophorectomy and pelvic lymph node sampling was performed in patients staged for endometrial cancer. Next to a significantly reduced operating time, the authors describe a significant increase in the amount of pelvic lymph nodes harvested with gaining experience \[[@CR23]\].

Although there are studies proving laparoscopic staging to be accurate and feasible \[[@CR8], [@CR10]--[@CR12], [@CR14], [@CR16]--[@CR18], [@CR21]\], many gynaecologic oncologists are still reluctant to adopt laparoscopic staging of ovarian cancer. Apart from inexperience with minimal invasive surgery, reluctance seems mainly based on doubts about the adequacy of the procedure. In particular to the number of lymph nodes obtained, possible risk of port site metastases, lack of tactile sensation and risk of intraoperative mass rupture have been questioned \[[@CR8], [@CR11], [@CR12], [@CR16]--[@CR18], [@CR22]\].

Several studies found similar numbers of lymph nodes obtained during laparoscopic and laparotomic staging \[[@CR11], [@CR21]\]. The overall number of lymph nodes obtained in our study is lower than in other studies. This could be due to the fact that we describe the learning curve from the first case. In other studies the surgeons are already experienced in the laparoscopic staging procedure and completed their learning curve before the series they describe. This is substantiated by the fact that the mean number of lymph nodes in the last eight patients (group 3) is indeed comparable with other authors. Besides we do not routinely perform a full lymph node dissection, but rather a sampling. In retrospect, the number of lymph nodes harvested in the first periods was too low. Future surgeons can avoid this by learning the procedure from a gynaecologic surgeon who already performed many lymph node dissections. Another concern is the risk of port site metastases due to direct wound contamination or implantation by instruments \[[@CR17]\]. Nagarsheth et al. demonstrated that the risk of port site metastases (ranging from 0% to 2.3%) is comparable to the incidence of implantation metastases observed after conventional laparotomy \[[@CR18], [@CR26]\]. The risk seems to be higher in patients with recurrent ovarian cancer or primary peritoneal malignancies in the presence of ascites \[[@CR16], [@CR26]\]. In our study no port site metastases were seen.

Intraoperative mass rupture in the primary laparoscopic staging procedure of early-stage ovarian cancer is also been thought to be a risk \[[@CR27]\]. However in secondary staging procedures, there is no risk of intraoperative mass rupture, since the tumour has already been removed in the first procedure. Intraoperative mass rupture leads to subsequent contamination of the peritoneal cavity with tumour cells and upstages the unexpected ovarian cancer from stage IA to stage IC. Upstaging of the tumour can create the need for adjuvant chemotherapy in patients with potentially curable disease \[[@CR18]\]. A multivariate analysis showed that capsular rupture caused by the surgeon did not significantly affect the prognosis in stage I and II ovarian cancer \[[@CR28]\]. In contrast to many others, Vergote et al. reported in a larger multivariate analysis that tumour rupture during surgery has a negative effect on prognosis \[[@CR29]\]. However, whether or not tumour rupture has a prognostic effect, it should not be considered specific to the laparoscopic procedure. The incidence of iatrogenic rupture of ovarian cancer cysts is similar in the laparoscopy and laparotomy groups \[[@CR17], [@CR19]\].

The rate of upstaging (having a higher stage after secondary staging procedure then presumed after the initial operation) found in this study is 32%, percentages found in other studies range between 0% (only nine patients described) \[[@CR20]\] and 41.7% \[[@CR12]\]. The high percentage of 41.7% found by Jung et al. is not entirely comparable to percentages found in other studies because they included a relatively high percentage of primary staging procedures. Our upstaging percentage is similar to upstaging rates in laparotomic staging ranging from 21.2% \[[@CR17]\] to 47% \[[@CR21]\].

The mean operation time in our series is comparable to the operating times reported by other authors, ranging from 149 to 377 min \[[@CR9], [@CR11]\]. The operating times found in studies with a laparotomy control group range from 218 to 290 min \[[@CR18], [@CR21]\]. The operation time for the laparoscopic procedures is generally longer than for a laparotomy. This should however be weighted against the patients\' benefit from a less traumatic technique, quicker recovery, shorter hospitalisation and the opportunity to start chemotherapy earlier \[[@CR10]\].

In the literature, postoperative stay for laparoscopic staging ranges from 2 to 10.6 days \[[@CR12], [@CR30]\]. We found a median of 4.0 days (range 2--6 days). Jung et al. found a mean postoperative stay of 10.6 days, which is substantially longer than in the most other studies. The postoperative stay in the laparotomic control groups ranges 5.8--14.5 days \[[@CR8], [@CR17]\].

In our series, four complications occurred. The complication rate for the laparoscopic staging procedure in early-stage ovarian cancer found in the literature ranges from 4.2% \[[@CR12]\] to 37.5% \[[@CR7]\]. The complication rate in laparoscopy is similar to or even less compared with laparotomy \[[@CR8], [@CR11]\].

Conclusion {#Sec9}
==========

This study is primarily focused on the effect of increasing experience of a single surgeon ('learning curve') in the laparoscopic staging of women with early ovarian cancer. We demonstrated a significant learning curve for the laparoscopic full staging procedure in early ovarian cancer. In our study the effect of the increased experience of the surgeon is mainly reflected in the increased number of lymph nodes harvested and not by the total operating time. Minimal invasive surgery requires a high level of skill and delicate dissection, and many gynaecologic oncologists have not yet been trained in this procedure. The laparoscopic staging procedure is a complex procedure and should best be learned under direct supervision of a skilled gynaecologic laparoscopic surgeon. If more gynaecologic oncologists would develop their experience with laparoscopic staging, this could have a great impact on applying laparoscopic surgery on a wider scale among women with early-stage ovarian cancer.
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